HRD Positive Advanced Ovarian Cancer
1 clinical trials · Condition
◉ Watch HRD Positive Advanced Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors (NCT06065059) | Tango Therapeutics, Inc. | 2023-12-08 |
Track HRD Positive Advanced Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.